These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2839395)

  • 21. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.
    Loy TS; Calaluce RD; Keeney GL
    Mod Pathol; 1996 Nov; 9(11):1040-4. PubMed ID: 8933513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma. A clinicopathologic study of 25 cases.
    Daya D; Nazerali L; Frank GL
    Am J Clin Pathol; 1992 Jun; 97(6):751-8. PubMed ID: 1595595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear reactivity for estrogen. A possible diagnostic tool in differentiating colon cancer metastases in the ovary from primary mucinous ovarian tumors.
    Darwish SA; D'Ablaing G; Taylor CR
    Cancer; 1988 Nov; 62(10):2203-6. PubMed ID: 3179933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
    Cao D; Ji H; Ronnett BM
    Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metastatic tumors in the ovary, difficulties of histologic diagnosis].
    Tamás J; Vereczkey I; Tóth E
    Magy Onkol; 2015 Sep; 59(3):205-13. PubMed ID: 26339910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The consequences of unsuspected secondary ovarian neoplasia: a clinical presentation of four case histories.
    Roley KM; Reza Hafez G; Buchler DA
    Gynecol Oncol; 1990 Feb; 36(2):277-80. PubMed ID: 2153625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of anti-carcinoembryonic antigen monoclonal antibodies for differentiating ovarian adenocarcinomas from gastrointestinal metastasis to the ovary.
    Pavelic ZP; Pavelic L; Pavelic K; Peacock JS
    Gynecol Oncol; 1991 Feb; 40(2):112-7. PubMed ID: 1707023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma.
    Berezowski K; Stastny JF; Kornstein MJ
    Mod Pathol; 1996 Apr; 9(4):426-9. PubMed ID: 8729984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity.
    Thor A; Muraro R; Gorstein F; Ohuchi N; Viglione M; Szpak CA; Johnston WW; Schlom J
    Cancer Res; 1987 Jan; 47(2):505-12. PubMed ID: 2431771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoradiometric assay of CA 125 in effusions. Comparison with carcinoembryonic antigen.
    Pinto MM; Bernstein LH; Brogan DA; Criscuolo E
    Cancer; 1987 Jan; 59(2):218-22. PubMed ID: 3467816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors.
    Wang J; El-Bahrawy MA
    Int J Gynecol Pathol; 2014 Mar; 33(2):166-75. PubMed ID: 24487472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunoperoxidase localization of tumour markers in ovarian cancer: the value of CEA, EMA, cytokeratin and DD9.
    Hammond RH; Bates TD; Clarke DG; Grant AG; Haines AM; Eustace DL; Heyderman E
    Br J Obstet Gynaecol; 1991 Jan; 98(1):73-83. PubMed ID: 1705435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical localisation of carcinoembryonic antigen (CEA) in malignant epithelial ovarian tumours using monoclonal antibodies.
    Gogate N; Deshmukh S
    Indian J Pathol Microbiol; 1995 Apr; 38(2):199-201. PubMed ID: 8919110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinction between endocervical and endometrial adenocarcinoma with immunoperoxidase staining of carcinoembryonic antigen in routine histological tissue specimens.
    Wahlström T; Lindgren J; Korhonen M; Seppälä M
    Lancet; 1979 Dec; 2(8153):1159-60. PubMed ID: 91890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucinous Ovarian Tumors.
    Mills AM; Shanes ED
    Surg Pathol Clin; 2019 Jun; 12(2):565-585. PubMed ID: 31097115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytopathology of ovarian lesions: the intraoperative approach.
    Jiménez-Ayala M; Jiménez-Ayala Portillo B
    Monogr Clin Cytol; 2011; 20():60-76. PubMed ID: 21160249
    [No Abstract]   [Full Text] [Related]  

  • 38. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors.
    Meriden Z; Yemelyanova AV; Vang R; Ronnett BM
    Am J Surg Pathol; 2011 Feb; 35(2):276-88. PubMed ID: 21263249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [MR Imaging of primary ovarian tumors with pathologic correlation].
    Bouic-Pagès E; Perrochia H; Mérigeaud S; Giacalone PY; Taourel P
    J Radiol; 2009; 90(7-8 Pt 1):787-802. PubMed ID: 19752784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.